Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$235.60
+4.6%
$231.30
$150.89
$250.74
$14.69B0.41693,204 shs252,047 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.48
-0.4%
$71.29
$31.77
$84.94
$13.44B1.022.72 million shs872,075 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$42.24
+3.6%
$38.47
$25.83
$57.99
$4.45B0.281.21 million shs470,487 shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$27.65
+1.4%
$27.06
$3.93
$83.60
$13.67B1.88333,967 shs32,013 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+4.43%+6.82%+9.45%-14.08%+21.10%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$235.60
+4.6%
$231.30
$150.89
$250.74
$14.69B0.41693,204 shs252,047 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.48
-0.4%
$71.29
$31.77
$84.94
$13.44B1.022.72 million shs872,075 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$42.24
+3.6%
$38.47
$25.83
$57.99
$4.45B0.281.21 million shs470,487 shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$27.65
+1.4%
$27.06
$3.93
$83.60
$13.67B1.88333,967 shs32,013 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+4.43%+6.82%+9.45%-14.08%+21.10%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.95
Moderate Buy$291.5623.75% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$87.7128.08% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.90
Moderate Buy$76.7581.72% Upside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CRNX, RGC, ASND, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetBuy$95.00 ➝ $102.00
4/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingOutperform$106.00
4/28/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Boost Price TargetMarket Outperform$96.00 ➝ $97.00
4/27/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$100.00
4/20/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Reiterated RatingSell (D-)
4/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$262.00 ➝ $292.00
4/9/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform$273.00
4/9/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageOutperform$100.00
4/8/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UpgradeModerate Buy
3/27/2026
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
Reiterated RatingSell (E+)
3/18/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOutperform$91.00 ➝ $106.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.04N/AN/A($2.97) per share-79.33
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.71N/AN/A($10.77) per share-6.36
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$7.70M578.35N/AN/A$9.71 per share4.35
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M-$4.40N/A22.59N/A-30.85%N/A-19.63%5/7/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.78N/A145.71N/A-144.39%N/A-74.43%5/7/2026 (Estimated)
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$465.32M-$4.94N/AN/AN/A-6,046.22%-41.46%-37.43%5/7/2026 (Estimated)
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$3.58MN/AN/AN/AN/AN/AN/AN/AN/A

Latest CRNX, RGC, ASND, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21N/AN/AN/A$362.56 millionN/A
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70N/AN/AN/A$178.64 millionN/A
5/7/2026Q1 2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.22N/AN/AN/A$8.51 millionN/A
2/26/2026Q4 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.37-$1.29+$0.08-$1.29$4.32 million$6.16 million
2/24/2026Q4 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million
2/12/2026Q4 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$0.06-$0.64-$0.58-$0.65$285.35 million$290.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.76
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
2.77
2.68
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
12.32
12.30
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.81 million167.94 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
210105.44 million99.11 millionOptionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10494.49 millionN/AN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$235.60 +10.32 (+4.58%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$68.48 -0.30 (-0.43%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$42.24 +1.49 (+3.64%)
As of 01:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$27.65 +0.38 (+1.39%)
As of 01:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.